Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

Viscerotropic disease (VTD) is defined as acute multiple organ system dysfunction that occurs following vaccination. The severity of VTD ranges from relatively mild multisystem disease to severe multiple organ system failure and death. The term VTD was first used shortly after the initial published reports in 2001 of febrile multiple organ system failure following yellow fever (YF) vaccination. To date, VTD has been reported only in association with YF vaccine and has been thus referred to as YF vaccine-associated viscerotropic disease (YEL-AVD)

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

Submitted by Repositório Arca ([email protected]) on 2018-07-25T12:28:46Z No. of bitstreams: 2 license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Bio-0013.pdf: 852994 bytes, checksum: d75cd666d8542005d0e6016ba864dbf2 (MD5)Approved for entry into archive by Priscila Nascimento ([email protected]) on 2018-10-04T20:06:06Z (GMT) No. of bitstreams: 2 Bio-0013.pdf: 852994 bytes, checksum: d75cd666d8542005d0e6016ba864dbf2 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5)Made available in DSpace on 2018-10-04T20:06:06Z (GMT). No. of bitstreams: 2 Bio-0013.pdf: 852994 bytes, checksum: d75cd666d8542005d0e6016ba864dbf2 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2012Centers for Disease Control and Prevention. Division of Global Migration and Quarantine. National Center for Emerging and Zoonotic Infectious Diseases. Atlanta, GA, USA. / Centers for Disease Control and Prevention. Division of Vector-Borne Diseases. National Center for Emerging and Zoonotic Infectious Diseases. Fort Collins, CO, USA.World Health Organization. Department of Immunization, Vaccines, and Biologicals. Geneva, Switzerland.Institut Pasteur. Agence de Médecine Préventive. Paris, France.Hospital das Clinicas. Division of Clinical Immunology and Allergy. São Paulo, SP, Brasil.Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública. Rio de Janeiro, Brasil.Sanofipasteur. Global Pharmacovigilance & Epidemiology. Lyon, France. Robert Koch Institute. Berlin, Germany. / Sanofipasteur. Division of Safety Monitoring and Risk Management for Pediatric and Travel Vaccines. Lyon, France.Department of International Health. Center for Immunization Research. Johns Hopkins Bloomberg School of Public Health. Baltimore, MD, USA.Barcelona Centre for International Health Research. Barcelona, Espanha.National Centre of Epidemiology. International Traveller’s Health and Vaccination Centre. Budapest, Hungary.Sanofipasteur. Global Pharmacovigilance and Epidemiology Department. Toronto, Canada.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Ministry of Health. Epidemiology Direction. Buenos Aires Province, Argentina.Rouen University Hospital. Pharmacovigilance Regional Center of Upper-Normandy. Rouen, Cedex, France.Federal Ministry of Health. Federal Secretariat. Maitama, Abuja, Nigeria.National Institutes of Health. National Institute of Allergy and Infectious Diseases. Division of AIDS. Bethesda, USA.Novartis Vaccines. Cambridge, USA.Harvard School of Public Health. Department of Global Health and Population. Boston, USA

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

Viscerotropic disease (VTD) is defined as acute multiple organ system dysfunction that occurs following vaccination. The severity of VTD ranges from relatively mild multisystem disease to severe multiple organ system failure and death. The term VTD was first used shortly after the initial published reports in 2001 of febrile multiple organ system failure following yellow fever (YF) vaccination. To date, VTD has been reported only in association with YF vaccine and has been thus referred to as YF vaccine-associated viscerotropic disease (YEL-AVD)

The PLATO Mission

International audiencePLATO (PLAnetary Transits and Oscillations of stars) is ESA's M3 mission designed to detect and characterise extrasolar planets and perform asteroseismic monitoring of a large number of stars. PLATO will detect small planets (down to <2 R_(Earth)) around bright stars (<11 mag), including terrestrial planets in the habitable zone of solar-like stars. With the complement of radial velocity observations from the ground, planets will be characterised for their radius, mass, and age with high accuracy (5 %, 10 %, 10 % for an Earth-Sun combination respectively). PLATO will provide us with a large-scale catalogue of well-characterised small planets up to intermediate orbital periods, relevant for a meaningful comparison to planet formation theories and to better understand planet evolution. It will make possible comparative exoplanetology to place our Solar System planets in a broader context. In parallel, PLATO will study (host) stars using asteroseismology, allowing us to determine the stellar properties with high accuracy, substantially enhancing our knowledge of stellar structure and evolution. The payload instrument consists of 26 cameras with 12cm aperture each. For at least four years, the mission will perform high-precision photometric measurements. Here we review the science objectives, present PLATO's target samples and fields, provide an overview of expected core science performance as well as a description of the instrument and the mission profile at the beginning of the serial production of the flight cameras. PLATO is scheduled for a launch date end 2026. This overview therefore provides a summary of the mission to the community in preparation of the upcoming operational phases